Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327561 | 0.82 | PTPN2 (0.46) | ALDH1A1HPGDRAB9ASMN1; SMN2PTPN2 | |
| SCHEMBL3324006 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDRAB9ASMN1; SMN2PTPN2 | |
| SCHEMBL3326866 | 0.77 | ALDH1A1 (0.53) | ALDH1A1HPGDRAB9ASMN1; SMN2MAOB | |
| SCHEMBL13293439 | 0.68 | ADRA2A (0.38) | ALDH1A1RAB9ASMN1; SMN2PTPN2PTPN1 | |
| SCHEMBL12359781 | 0.68 | CHRM4 (0.49) | RAB9AGPR119 | |
| SCHEMBL23619645 | 0.66 | CA1 (0.47) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5106835 | 0.66 | CYP17A1 (0.54) | NAMPT | |
| SCHEMBL6826022 | 0.66 | USP2 (0.39) | HPGDSMN1; SMN2GPR119 | |
| SCHEMBL20364200 | 0.66 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL25489259 | 0.64 | NAMPT (0.43) | ALDH1A1RAB9ASMN1; SMN2PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148865-B1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2148865-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | Genentech, Inc. (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008137408-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | WNT1, WNT3A, CTNNB1 | ALDH1A1 1479/4885HPGD 2944/4885RAB9A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.